Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28492827 | 0.77 | KMT2A (0.51) | KMT2AMEN1LMNANOTUMSMN1; SMN2 | |
| SCHEMBL918756 | 0.73 | NOTUM (0.47) | KMT2AGAAMEN1NOTUMSMN1; SMN2 | |
| SCHEMBL25412576 | 0.70 | ELANE (0.46) | BCHEGAAALDH1A1 | |
| Biphenyl SCHEMBL2202263 | 0.70 | NOTUM (0.44) | KMT2AGAAMEN1NOTUMSMN1; SMN2 | |
| SCHEMBL28619407 | 0.69 | KMT2A (0.73) | KMT2AMEN1LMNANOTUMSMN1; SMN2 | |
| SCHEMBL3079013 | 0.69 | TP53 (0.54) | KMT2ABCHEGAAMEN1SMN1; SMN2 | |
| SCHEMBL13689910 | 0.69 | BCHE (0.41) | KMT2ABCHEGAAMEN1LMNA | |
| SCHEMBL11030328 | 0.69 | GAA (0.44) | KMT2ABCHEGAAMEN1LMNA | |
| SCHEMBL4502875 | 0.68 | — | — | |
| SCHEMBL753707 | 0.68 | GAA (0.43) | KMT2ABCHEGAAMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0928311-B1 | SHAPING OBJECT WITH REACTIVE FUNCTIONS | BIOTECHNOLOG FORSCHUNG GMBH (DE) | 2003-04-09 | — | — | EP | claimed |
| WO-2020128525-A1 | NRTI THERAPIES | THE UNIVERSITY OF LIVERPOOL (GB) | 2020-06-25 | — | — | WO | disclosed |
| US-10316371-B2 | Screening methods for identifying specific Staphylococcus aureus inhibitors | TRANA DISCOVERY, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| CN-102015697-B | Amide derivatives and pharmaceutical compositions containing the same | DAINIPPON SUMITOMO PHARMA CO | 2015-06-17 | — | — | CN | disclosed |
| EP-2256114-B1 | AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | DAINIPPON SUMITOMO PHARMA CO (JP) | 2014-06-25 | — | — | EP | disclosed |
| US-20140163037-A1 | SCREENING METHODS FOR IDENTIFYING SPECIFIC STAPHYLOCOCCUS AUREUS INHIBITORS | TRANA DISCOVERY, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| EP-2691542-A1 | SCREENING METHODS FOR IDENTIFYING SPECIFIC STAPHYLOCOCCUS AUREUS INHIBITORS | Trana Discovery, Inc. (US) | 2014-02-05 | — | — | EP | disclosed |
| US-8431341-B2 | Compositions and methods for the identification of inhibitors of protein synthesis | TRANA DISCOVERY, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| WO-2012135416-A1 | SCREENING METHODS FOR IDENTIFYING SPECIFIC STAPHYLOCOCCUS AUREUS INHIBITORS | TRANA DISCOVERY, INC. (US) | 2012-10-04 | — | — | WO | disclosed |
| US-8232378-B2 | Compositions and methods for the identification of inhibitors of protein synthesis | TRANA DISCOVERY, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-20030166930-A1 | Process for synthesis of heteroaryl-substituted urea compounds useful as antiinflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-09-04 | — | — | US | disclosed |
| US-20030166931-A1 | Process for synthesis of heteroaryl-substituted urea compounds useful as antiinflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-09-04 | — | — | US | disclosed |
| US-6583282-B1 | Formation of a urea by reacting an aromatic carbamate with a aromatic amine | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-06-24 | — | — | US | disclosed |
| US-20030109703-A1 | Polymorph and process for preparing same | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-06-12 | — | — | US | disclosed |
| EP-0928311-B1 | SHAPING OBJECT WITH REACTIVE FUNCTIONS | BIOTECHNOLOG FORSCHUNG GMBH (DE) | 2003-04-09 | — | — | EP | disclosed |
| EP-1200411-A2 | NOVEL PROCESS FOR SYNTHESIS OF HETEROARYL-SUBSTITUTED UREA COMPOUNDS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2002-05-02 | — | — | EP | disclosed |
| US-6294555-B1 | SEROTONIN HT3 RECEPTOR ANTAGONIST FOR GASTROINTESTINAL DISORDERS | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2001-09-25 | — | — | US | disclosed |
| EP-1076055-A1 | 1- (1-SUBSTITUTED-4-PIPERIDINYL)METHYL]-4-PIPERIDINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, MEDICINAL COMPOSITIONS CONTAINING THE SAME AND INTERMEDIATES OF THESE COMPOUNDS | Dainippon Pharmaceutical Co., Ltd. (JP) | 2001-02-14 | — | — | EP | disclosed |
| WO-2001004115-A2 | NOVEL PROCESS FOR SYNTHESIS OF HETEROARYL-SUBSTITUTED UREA COMPOUNDS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2001-01-18 | — | — | WO | disclosed |
| EP-0567841-A2 | Fluorescently marked compounds, their preparation and use | MERCK PATENT GmbH (DE) | 1993-11-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166931-A1 | Process for synthesis of heteroaryl-substituted urea compounds useful as antiinflammatory agents | URB2, UGT1A1, PURB | KMT2A 3209/4885BCHE 2355/4885GAA 2063/4885 |
| US-20140163037-A1 | SCREENING METHODS FOR IDENTIFYING SPECIFIC STAPHYLOCOCCUS AUREUS INHIBITORS | NSUN3, RNGTT, TRMT1 | KMT2A 1190/4885BCHE 3618/4885GAA 3434/4885 |
| US-20030109703-A1 | Polymorph and process for preparing same | UGT1A1, CYP1A1, CYP1B1 | KMT2A 3719/4885BCHE 3847/4885GAA 1592/4885 |
| US-10316371-B2 | Screening methods for identifying specific Staphylococcus aureus inhibitors | NSUN3, RNGTT, TRMT1 | KMT2A 1190/4885BCHE 3618/4885GAA 3434/4885 |
| US-20030166930-A1 | Process for synthesis of heteroaryl-substituted urea compounds useful as antiinflammatory agents | URB2, UGT1A1, PURB | KMT2A 3209/4885BCHE 2355/4885GAA 2063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.